Literature DB >> 9141520

Variability of glutathione levels in normal breast tissue and subcutaneous fat during the menstrual cycle: an in vivo study with microdialysis technique.

C Dabrosin1, K Ollinger, U Ungerstedt, M Hammar.   

Abstract

A small increase in the risk of breast cancer has been reported after long term use of combined estrogen-progestagen treatment. Free oxygen radicals and antioxidants such as glutathione are involved in the regulation of proliferation and apoptosis and thereby in carcinogenesis. To study whether the glutathione levels are sex hormone dependent, we used the microdialysis technique to measure the in vivo concentrations of glutathione in breast tissue and sc fat during the menstrual cycle. Six healthy women (23-32 yr old) were investigated early in the follicular phase and the midluteal phase. Two 60-min fractions each were collected by microdialysis of periumbilical fat and breast tissue, respectively. The samples were stored at -70 C and analyzed by high performance liquid chromatography. Glutathione concentrations increased in the midluteal phase compared to those in the follicular phase in both adipose tissue and breast tissue (P < 0.05). The variability of glutathione levels during the menstrual cycle, with higher levels late in the menstrual cycle, indicates that the antioxidant system could be sex hormone dependent. This may be of importance in breast cancer development.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9141520     DOI: 10.1210/jcem.82.5.3957

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

Review 1.  p66Shc--a longevity redox protein in human prostate cancer progression and metastasis : p66Shc in cancer progression and metastasis.

Authors:  Mythilypriya Rajendran; Paul Thomes; Li Zhang; Suresh Veeramani; Ming-Fong Lin
Journal:  Cancer Metastasis Rev       Date:  2010-03       Impact factor: 9.264

2.  Inflammation induced by MMP-9 enhances tumor regression of experimental breast cancer.

Authors:  Karin Söderlund Leifler; Susanne Svensson; Annelie Abrahamsson; Christina Bendrik; Jennifer Robertson; Jack Gauldie; Anna-Karin Olsson; Charlotta Dabrosin
Journal:  J Immunol       Date:  2013-03-15       Impact factor: 5.422

Review 3.  A novel role of Shc adaptor proteins in steroid hormone-regulated cancers.

Authors:  Syed Mahfuzul Alam; Mythilypriya Rajendran; Shouqiang Ouyang; Suresh Veeramani; Li Zhang; Ming-Fong Lin
Journal:  Endocr Relat Cancer       Date:  2008-11-11       Impact factor: 5.678

4.  Tamoxifen and flaxseed alter angiogenesis regulators in normal human breast tissue in vivo.

Authors:  Ulrika W Nilsson Åberg; Niina Saarinen; Annelie Abrahamsson; Tarja Nurmi; Sofia Engblom; Charlotta Dabrosin
Journal:  PLoS One       Date:  2011-09-30       Impact factor: 3.240

Review 5.  p66Shc as a switch in bringing about contrasting responses in cell growth: implications on cell proliferation and apoptosis.

Authors:  Sahar S Bhat; Deepak Anand; Firdous A Khanday
Journal:  Mol Cancer       Date:  2015-04-08       Impact factor: 27.401

6.  Long-term patterns of urinary pyroglutamic acid in healthy humans.

Authors:  Richard S Lord
Journal:  Physiol Rep       Date:  2016-02

7.  Adipokines and Vascular Endothelial Growth Factor in Normal Human Breast Tissue in Vivo - Correlations and Attenuation by Dietary Flaxseed.

Authors:  Vivian Morad; Annelie Abrahamsson; Preben Kjölhede; Charlotta Dabrosin
Journal:  J Mammary Gland Biol Neoplasia       Date:  2016-04-08       Impact factor: 2.673

8.  Tissue specific expression of extracellular microRNA in human breast cancers and normal human breast tissue in vivo.

Authors:  Annelie Abrahamsson; Charlotta Dabrosin
Journal:  Oncotarget       Date:  2015-09-08

9.  Biological Variation in Peripheral Inflammation and Oxidative Stress Biomarkers in Individuals with Gaucher Disease.

Authors:  Siddhee A Sahasrabudhe; Marcia R Terluk; Kyle D Rudser; James C Cloyd; Reena V Kartha
Journal:  Int J Mol Sci       Date:  2022-08-16       Impact factor: 6.208

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.